Kodosil Bio was established under an agreement between BioMotiv and BioAtla in order to develop and commercialize BioAtla's Th22 pathway directed antibody compound for the treatment of inflammatory bowel diseases and oncologic indications. 

We believe BioMotiv will be an ideal partner to take the antibody forward into the clinic, building on our solid discovery foundation that demonstrates the value of this antibody in the potential treatment of a variety of disease indications where there is considerable unmet need in large market opportunities
— Jay M. Short, Ph.D., President and CEO of BioAtla

The therapeutic antibody is directed at a novel validated target in the Th22 cell/Il-22 pathway that plays a key role in gastrointestinal autoimmune and inflammatory processes, as evidenced by changes in expression in IBD and colorectal cancer (CRC) patients.